bexarotene has been researched along with Benign Neoplasms in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Atigadda, VR; Boerma, LJ; Brouillette, WJ; Christov, K; Desphande, A; Grubbs, CJ; Lobo-Ruppert, S; Moeinpour, FL; Muccio, DD; Smith, CD; Vines, KK; Xia, G | 1 |
| Brown, PH; Contreras, A; Dimond, E; Heckman-Stoddard, BM; Hernandez, M; Khan, SA; Lee, JJ; Liu, DD; Mays, C; Muzzio, M; Patel, AB; Perloff, M; Sepeda, V; Thomas, PS; Vornik, LA; Weber, D | 1 |
| Al-Madhagi, H; Alasmari, AF; Alasmari, F; Alharbi, M; Khan, M; Khan, MQ; Shahab, M; Wadood, A; Zeb, A; Zheng, G | 1 |
| Chowdhury, AS; Hung, PY; Leal, AS; Liby, KT | 1 |
| Ding, Y; Dvornikov, AV; Ekker, SC; Herrmann, J; Hsiai, TK; Kim, M; Lin, X; Lowerison, M; Ma, X; Norton, N; Qiu, Q; Wang, Y; Wang, Z; Xu, X; Yu, Y; Zhang, H; Zhu, P | 1 |
| Leal, AS; Liby, KT; Moerland, JA; Reich, LA; Zhang, D | 1 |
| Chen, Y; Cheng, F; Li, G; Shen, D; Wu, Y; Xia, L; Yu, X | 1 |
| Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F | 1 |
| Cao, X; Guo, Y; Luan, Y; Qi, L; Zhang, P | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, WL | 1 |
| Collins, B; Hwang, J; Malik, SM; Marshall, J; Pishvaian, M; Ramzi, P | 1 |
| Hamnvik, OP; Larsen, PR; Marqusee, E | 1 |
| Chang, WC; Clapper, ML; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; McCormick, DL; Pereira, MA; Steele, VE | 1 |
| Baso, JC; Bhogal, JS; Browder, DO; Furmick, JK; Gray, GM; Groy, TL; Huynh, CC; Jurutka, PW; Kaneko, I; Kwon, JS; Lemming, B; Marcus, LM; Marshall, PA; Montano, LA; Prentice, JL; Quezada, A; Reyes, NM; Saini, P; Tsosie, DG; van der Vaart, A; Wagner, CE; Walsh, AN; Yang, J | 1 |
| Farol, LT; Hymes, KB | 1 |
| Mei, JH; Wang, MW | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, W; Suresh, R; Wildi, JD | 1 |
| Benedetti, FM; Crisp, M; Heyman, R; Kris, MG; Loewen, GR; Miller, VA; Pfister, DG; Rigas, JR; Straus, D; Truglia, JA; Verret, AL; Warrell, RP | 1 |
| Dahut, W; Geiser, R; Gill, GM; Hawkins, MJ; Jaunakais, D; Loewen, G; Marshall, JL; Ness, E; Rizvi, NA; Truglia, JA; Ulm, EH | 1 |
| Hurst, RE | 1 |
| Anderson, B; Smith, MA | 1 |
9 review(s) available for bexarotene and Benign Neoplasms
| Article | Year |
|---|---|
Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer.
Topics: Bexarotene; Humans; Immune System; Inflammation; Neoplasms; Retinoid X Receptors; Tumor Microenvironment | 2023 |
Potential therapeutic uses of rexinoids.
Topics: Bexarotene; Humans; Neoplasms; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Tumor Microenvironment | 2021 |
Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bexarotene; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplasms; Neovascularization, Pathologic | 2018 |
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hypothyroidism; Interferon-alpha; Interleukin-2; Lenalidomide; Neoplasms; Recombinant Fusion Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Diseases; Thyroid Gland; Thyroid Hormones; Thyroxine | 2013 |
Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.
Topics: Animals; Antineoplastic Agents; Bexarotene; Humans; Neoplasms; Retinoid X Receptors; Tetrahydronaphthalenes | 2016 |
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hyperthyroidism; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Iodine Radioisotopes; Ipilimumab; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Radioimmunotherapy; Recombinant Fusion Proteins; Recombinant Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Thyroiditis, Autoimmune | 2011 |
Bexarotene: a clinical review.
Topics: Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Humans; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Neoplasms; Skin Neoplasms; Tetrahydronaphthalenes | 2004 |
[Advances in studies on selective RXR ligands].
Topics: Alitretinoin; Animals; Antineoplastic Agents; Bexarotene; Humans; Ligands; Neoplasms; Retinoid X Receptors; Retinoids; Structure-Activity Relationship; Tetrahydronaphthalenes; Tretinoin | 2005 |
Bexarotene ligand pharmaceuticals.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Contraindications; Drugs, Investigational; Humans; Neoplasms; Receptors, Retinoic Acid; Retinoid X Receptors; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription Factors | 2000 |
6 trial(s) available for bexarotene and Benign Neoplasms
| Article | Year |
|---|---|
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.
Topics: Administration, Topical; Antineoplastic Agents; Bexarotene; Female; Humans; Neoplasms | 2023 |
A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Male; Middle Aged; Neoplasms; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones | 2008 |
A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Survival Rate; Taxoids; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2011 |
A phase I study of docetaxel and bexarotene.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Docetaxel; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Taxoids; Tetrahydronaphthalenes | 2008 |
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Area Under Curve; Bexarotene; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Tetrahydronaphthalenes | 1997 |
A Phase I study of LGD1069 in adults with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Headache; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 1999 |
7 other study(ies) available for bexarotene and Benign Neoplasms
| Article | Year |
|---|---|
Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
Topics: Humans; Kruppel-Like Factor 4; Ligands; Molecular Conformation; Neoplasms; Retinoid X Receptors; Retinoids | 2014 |
Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy.
Topics: Bexarotene; Blood Group Antigens; Early Detection of Cancer; Histone Deacetylase 6; Humans; Immunotherapy; Neoplasms; Oxymorphone | 2023 |
Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity.
Topics: Animals; Bexarotene; Cardiotonic Agents; Cardiotoxicity; Disease Models, Animal; Endothelial Cells; Heart; Humans; Isotretinoin; Myocardium; Neoplasms; Pericardium; Retinoid X Receptor alpha; Zebrafish; Zonula Occludens-1 Protein | 2020 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Head and Neck Neoplasms; Intestinal Neoplasms; Male; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Neoplasms; Pyrazoles; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sulfonamides; Tetrahydronaphthalenes; Urinary Bladder Neoplasms | 2012 |
Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Line, Tumor; Halogenation; Humans; Lymphoma, T-Cell, Cutaneous; Molecular Docking Simulation; Neoplasms; Protein Multimerization; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
New genetic mechanism associated with thyroid-related diseases.
Topics: Anticarcinogenic Agents; Bexarotene; Female; Humans; Hypothyroidism; Incidence; Male; Neoplasms; Tetrahydronaphthalenes; Thyroid Gland; Thyroid Hormones; Thyrotropin; United States | 1999 |
Where to next with retinoids for cancer therapy?
Topics: Alitretinoin; Antineoplastic Agents; Bexarotene; Humans; Isotretinoin; Neoplasms; Retinoids; Tetrahydronaphthalenes; Tretinoin | 2001 |